SLC30A3 Antibody

What is SLC30A3 and what is its role in neuronal function?

SLC30A3 (Solute Carrier Family 30 Member 3), commonly known as ZnT3, is a member of the SLC30 family of zinc transporters. It plays a crucial role in promoting the influx of zinc ions into synaptic vesicles of glutamatergic neurons from the cytoplasm, intracellular organelles, or to the outside of the cell. This transporter is primarily responsible for maintaining high intravesicular zinc content and is selectively located on the vesicles of zinc-secreting neurons, particularly in brain regions such as the hippocampus and neocortex. Ionic zinc facilitated by ZnT3 is ubiquitously found throughout synapses of the mammalian central nervous system, where it plays fundamental roles in synaptic function and plasticity .

What is the molecular structure of SLC30A3/ZnT3?

ZnT3 structure is predicted to contain six transmembrane spanning domains that form a pore lined with a histidine-rich loop . This structural arrangement is characteristic of the cation diffusion facilitator (CDF) transporter family to which ZnT3 belongs. The human SLC30A3 gene is located at chromosome 2p23.3, and the encoded protein has a molecular mass of approximately 41.945 kDa . The protein contains cytoplasmic amino- and carboxy-terminal tails, with the C-terminal region being particularly important for antibody recognition in experimental applications .

What happens in systems with ZnT3 deficiency?

Knockout of ZnT3 leads to the absence of histochemically reactive zinc in the terminals of zincergic neurons . This has significant implications for understanding zinc homeostasis in the brain and its role in neurological function. Research using ZnT3 knockout models has provided valuable insights into the physiological importance of vesicular zinc in neurotransmission, synaptic plasticity, and potentially in neurological disorders. The absence of ZnT3 affects zinc-dependent processes in synaptic vesicles, which may alter neurotransmitter release and synaptic function .

How should researchers select the appropriate anti-SLC30A3 antibody for specific applications?

When selecting an anti-SLC30A3 antibody, researchers should consider several factors based on their experimental requirements:

• Epitope specificity: For SLC30A3/ZnT3, antibodies targeting the C-terminal region have shown high specificity and sensitivity. The dominant epitope(s) of ZnT3 are reported to be located at amino acids 268-369, which are conformational rather than linear .

• Species reactivity: Verify cross-reactivity with your experimental model (human, mouse, rat). For example, Anti-ZnT3 Antibody (#AZT-013) has demonstrated reactivity with rat, mouse, and human samples in various applications .

• Application compatibility: Confirm the antibody has been validated for your specific application (Western blot, immunohistochemistry, immunofluorescence, etc.). The Anti-ZnT3 Antibody has been validated for Western blot analysis of rat and mouse brain lysates at 1:500 dilution, human SH-SY5Y neuroblastoma cell lysate at 1:200, and immunohistochemical staining of rat brain sections at 1:600 .

• Validation data: Review provided data showing specificity, such as preincubation with blocking peptides, which should eliminate signal as demonstrated with the ZnT3/SLC30A3 Blocking Peptide (#BLP-ZT013) .

What are the recommended validation strategies for SLC30A3 antibodies?

To ensure antibody specificity and reliability in SLC30A3 research, implement these validation strategies:

• Peptide competition assays: Preincubate the antibody with its immunizing peptide before application. This should eliminate specific binding, as demonstrated with Anti-ZnT3 Antibody when preincubated with ZnT3/SLC30A3 Blocking Peptide .

• Positive and negative tissue controls: Test the antibody on tissues known to express SLC30A3 positively (hippocampus, neocortex) and negatively. This approach is specifically mentioned as part of validation protocols by antibody suppliers .

• Knockout/knockdown controls: When available, samples from SLC30A3 knockout animals or cells with knockdown expression provide excellent negative controls.

• Multiple antibody verification: Use antibodies from different sources or targeting different epitopes to confirm specificity of staining patterns.

• Signal correlation with known expression patterns: Verify that immunostaining patterns match established ZnT3 distribution, such as the mossy fiber terminal field in the CA3 region of the hippocampus .

What are the optimal protocols for Western blot analysis using SLC30A3 antibodies?

For optimal Western blot results with SLC30A3 antibodies, follow these methodological guidelines:

• Sample preparation:

  • For brain tissue: Homogenize in RIPA buffer supplemented with protease inhibitors

  • For neuronal cell lines (e.g., SH-SY5Y): Lyse cells directly in sample buffer containing reducing agent

• Antibody dilution:

  • For rat and mouse brain lysates: 1:500 dilution of Anti-ZnT3 Antibody (#AZT-013)

  • For human neuroblastoma cell lysate: 1:200 dilution

• Controls:

  • Positive control: Brain lysates (rat or mouse) are ideal positive controls

  • Negative control: Non-neuronal tissues or antibody preincubated with blocking peptide

  • Use of blocking peptide (e.g., ZnT3/SLC30A3 Blocking Peptide #BLP-ZT013) at appropriate concentration to confirm specificity

• Detection parameters:

  • Expected molecular weight: ~42 kDa

  • Secondary antibody selection should match host species of primary antibody

• Troubleshooting:

  • If high background occurs, increase blocking time and washing steps

  • For weak signals, extend primary antibody incubation time (overnight at 4°C)

What is the recommended procedure for immunohistochemical detection of SLC30A3/ZnT3?

For immunohistochemical detection of SLC30A3/ZnT3 in brain tissue, follow this methodological approach:

• Tissue preparation:

  • Use immersion-fixed, free-floating brain frozen sections

  • For optimal results with hippocampal tissue, 4% paraformaldehyde fixation is recommended

• Antibody application:

  • Anti-ZnT3 Antibody (#AZT-013) at 1:600 dilution has been validated for rat brain sections

  • Incubate sections overnight at 4°C for optimal signal-to-noise ratio

• Detection and co-localization:

  • ZnT3 (green) can be visualized in the mossy fiber terminal field of the CA3 region

  • Co-staining with synaptophysin (red) helps to confirm synaptic localization

  • Nuclear counterstaining with DAPI (blue) provides structural context

• Analysis approach:

  • Examine co-localization particularly in the mossy fiber region

  • Analyze expression patterns relative to known neuroanatomical structures

• Controls and validation:

  • Include sections from ZnT3 knockout mice when available

  • Use peptide-blocked antibody as negative control

How should SLC30A3 antibodies be stored and handled for optimal performance?

Proper storage and handling of SLC30A3 antibodies is crucial for maintaining reactivity and specificity:

• Initial storage upon receipt:

  • Store lyophilized antibody powder at -20°C upon arrival

  • Avoid repeated freeze-thaw cycles of reconstituted antibody

• Reconstitution protocol:

  • Add 25 μL, 50 μL, or 0.2 mL double distilled water (DDW) depending on the sample size

  • The reconstituted solution can be stored at 4°C for up to 1 week

  • For longer periods, prepare small aliquots and store at -20°C

• Pre-use preparation:

  • Centrifuge all antibody preparations before use (10000 x g for 5 min)

  • Bring to room temperature before opening vials to prevent condensation

• Working dilution storage:

  • Prepare working dilutions fresh on day of use when possible

  • If storing diluted antibody, add carrier protein (BSA) at 1-5%

• Avoiding contamination:

  • Use sterile technique when handling antibody solutions

  • Prepare aliquots in a clean environment to prevent contamination

How can researchers distinguish between specific and non-specific binding in SLC30A3 antibody applications?

To distinguish between specific and non-specific binding when using SLC30A3 antibodies:

• Peptide blocking controls: Compare staining patterns between samples probed with the antibody alone versus antibody preincubated with blocking peptide. Specific signals should be eliminated in blocked samples, as demonstrated with Anti-ZnT3 Antibody when preincubated with ZnT3/SLC30A3 Blocking Peptide .

• Anatomical correlation: Verify that staining patterns match known ZnT3 distribution. For example, in the hippocampus, ZnT3 is highly expressed in the mossy fiber terminal field of the CA3 region .

• Co-localization studies: Use dual-labeling with established synaptic markers like synaptophysin. Authentic ZnT3 signals should show substantial co-localization with synaptic markers in regions like the mossy fiber terminal field .

• Molecular weight verification: In Western blots, specific binding should produce a predominant band at approximately 42 kDa, corresponding to the predicted molecular weight of ZnT3 .

• Comparison across species: Consistent patterns across rat, mouse, and human samples (accounting for known species differences) can provide additional confidence in specificity.

What are common technical challenges when working with SLC30A3 antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with SLC30A3 antibodies, along with recommended solutions:

• High background in immunohistochemistry:

  • Increase blocking time (use 5-10% normal serum from secondary antibody species)

  • Decrease primary antibody concentration (try 1:800-1:1000 instead of 1:600)

  • Extend washing steps (4-5 washes of 10 minutes each)

  • Use 0.3% Triton X-100 in washing buffer to reduce non-specific membrane binding

• Weak or absent signal in Western blot:

  • Increase protein loading (50-100 μg of total protein)

  • Decrease antibody dilution (1:200 for challenging samples)

  • Extend exposure time

  • Use enhanced chemiluminescence detection systems

  • Verify sample preparation protocol preserves protein integrity

• Multiple bands in Western blot:

  • Confirm appropriate reducing conditions in sample buffer

  • Use fresher tissue samples to minimize protein degradation

  • Add protease inhibitors to all buffers during sample preparation

  • Compare with peptide-blocked control to identify which bands are specific

• Inconsistent results between experiments:

  • Standardize all protocols including fixation time, antibody incubation time and temperature

  • Prepare larger batches of working dilutions to use across experiments

  • Process all samples to be compared simultaneously

  • Include internal controls in each experiment

How can SLC30A3 antibodies be utilized in studying neurodegenerative disorders?

SLC30A3 antibodies offer valuable tools for investigating neurodegenerative disorders with these methodological approaches:

• Comparative expression analysis:

  • Quantify ZnT3 protein levels in post-mortem brain tissue from patients versus controls

  • Use Western blot with Anti-ZnT3 Antibody at appropriate dilutions (1:200-1:500) to detect changes in expression levels

  • Perform densitometric analysis normalized to loading controls

• Synaptic integrity assessment:

  • ZnT3 can serve as a marker for zinc-containing glutamatergic terminals

  • Double-label with synaptophysin to assess co-localization changes in disease states

  • Quantify terminal density and morphology in regions vulnerable to degeneration

• Zinc homeostasis disruption:

  • Correlate ZnT3 expression changes with zinc dyshomeostasis in brain regions

  • Combine immunohistochemistry with zinc-specific detection methods

• Animal model validation:

  • Compare ZnT3 expression patterns between disease models and human pathology

  • Use standardized staining protocols to allow direct comparisons

• Therapeutic intervention assessment:

  • Monitor ZnT3 levels and localization in response to experimental treatments

  • Use as a biomarker for synaptic preservation in intervention studies

What approaches are recommended for studying SLC30A3 in the context of synaptic plasticity?

To investigate SLC30A3's role in synaptic plasticity, implement these research approaches:

• Temporal expression analysis:

  • Track ZnT3 expression changes during development or after plasticity-inducing stimuli

  • Use Western blot analysis with consistent antibody dilutions (1:500) for quantitative comparisons

• Subcellular localization studies:

  • Employ immunogold electron microscopy to precisely localize ZnT3 at synapses

  • Compare distribution patterns before and after synaptic activity

• Functional correlations:

  • Combine electrophysiological recordings with immunohistochemical analysis

  • Correlate ZnT3 expression with synaptic strength in specific neuronal circuits

• Genetic manipulation approaches:

  • Use conditional knockout models to examine acute versus chronic effects of ZnT3 loss

  • Correlate molecular findings with behavioral and electrophysiological outcomes

• Activity-dependent regulation:

  • Examine activity-dependent changes in ZnT3 expression and localization

  • Use stimulation paradigms (chemical LTP/LTD) coupled with immunocytochemistry

How can researchers effectively study interactions between SLC30A3 and other synaptic proteins?

To investigate interactions between SLC30A3/ZnT3 and other synaptic proteins, employ these methodological strategies:

• Co-immunoprecipitation (Co-IP):

  • Use Anti-ZnT3 Antibody to pull down ZnT3 and associated proteins

  • Alternatively, use antibodies against candidate interacting proteins to pull down complexes

  • Analyze precipitates by Western blot to detect ZnT3 and potential binding partners

  • Include appropriate controls: IgG control, input samples, and blocking peptide controls

• Proximity ligation assay (PLA):

  • Detect protein-protein interactions in situ at synapses

  • Combine Anti-ZnT3 Antibody with antibodies against candidate interacting proteins

  • Quantify PLA signals at specific synaptic compartments

• Immunofluorescence co-localization:

  • Perform double or triple labeling with ZnT3 and synaptic proteins

  • Use confocal microscopy to assess spatial relationships

  • Quantify co-localization using appropriate statistical methods

  • As demonstrated in the search results, co-localization studies between ZnT3 and synaptophysin reveal their relationship in the mossy fiber region

• FRET/FLIM analysis:

  • For higher resolution interaction studies, use fluorescence resonance energy transfer

  • Requires fluorophore-conjugated antibodies or expression of fluorescent fusion proteins

• Mass spectrometry approaches:

  • Identify novel ZnT3-interacting proteins through immunoprecipitation coupled with mass spectrometry

  • Validate candidate interactions with the methods above

How does SLC30A3 differ from other zinc transporters in the SLC30 family?

ZnT3 (SLC30A3) has several distinctive characteristics compared to other members of the SLC30 family:

• Expression pattern:

  • ZnT3 is selectively located on vesicles of zinc-secreting neurons, particularly in brain regions such as the hippocampus and neocortex

  • Other ZnT transporters show broader tissue distribution or different subcellular localization

• Functional specialization:

  • ZnT3 is specifically responsible for accumulating zinc in synaptic vesicles of glutamatergic neurons

  • Other family members (like ZnT1) primarily function in zinc efflux across the plasma membrane, while ZnT2 promotes zinc accumulation in lysosomes

• Structural features:

  • While sharing the common six transmembrane domain structure of the cation diffusion facilitator family, ZnT3 contains unique sequences in its histidine-rich loop region

  • These unique features likely contribute to its specific function in synaptic vesicles

• Physiological impact:

  • Knockout of ZnT3 specifically eliminates histochemically reactive zinc in synaptic terminals

  • Other ZnT family members may have broader systemic effects when disrupted

• Clinical associations:

  • Unlike ZnT8 (SLC30A8), which has established associations with diabetes mellitus , ZnT3's clinical associations are primarily with neurological functions and potentially neurodegenerative disorders

What methodological considerations are important when studying multiple zinc transporters simultaneously?

When investigating multiple zinc transporters concurrently, researchers should consider these methodological approaches:

• Antibody specificity validation:

  • Test for cross-reactivity between related zinc transporter antibodies

  • Include appropriate controls for each antibody (blocking peptides, knockout samples)

  • When possible, use antibodies raised against unique regions of each transporter

• Expression analysis standardization:

  • Use consistent protein extraction methods across samples

  • Apply identical Western blotting conditions (protein amount, transfer time, etc.)

  • Normalize to appropriate housekeeping proteins for quantitative comparisons

• Co-localization analysis:

  • When examining multiple transporters in the same sample, use carefully selected fluorophore combinations to minimize spectral overlap

  • Include single-stained controls to confirm absence of bleed-through

  • Use sequential scanning in confocal microscopy to minimize cross-talk

• Functional distinction:

  • Design experiments that can distinguish the specific roles of different transporters

  • Consider selective inhibitors or genetic manipulation approaches

  • Measure zinc levels in specific subcellular compartments relevant to each transporter

• Data analysis and integration:

  • Develop comprehensive analytical approaches that account for potential interactions between transporters

  • Consider systems biology approaches for understanding transporter networks

  • Correlate expression patterns with functional outcomes

What emerging techniques can enhance SLC30A3 research beyond traditional antibody applications?

Beyond conventional antibody applications, these emerging techniques can advance SLC30A3 research:

• CRISPR/Cas9 genome editing:

  • Generate tagged endogenous SLC30A3 to study physiological expression

  • Create specific domain mutations to investigate structure-function relationships

  • Develop conditional knockout models for temporal and spatial control

• Super-resolution microscopy:

  • Apply STORM, STED, or PALM techniques for nanoscale localization of ZnT3

  • Combine with synaptic markers for detailed mapping of synaptic organization

  • Visualize dynamic changes in ZnT3 distribution during synaptic activity

• Live imaging approaches:

  • Develop fluorescent protein fusions that maintain ZnT3 functionality

  • Monitor trafficking and localization in response to neuronal activity

  • Combine with zinc sensors to correlate transporter localization with zinc dynamics

• Single-cell transcriptomics/proteomics:

  • Analyze cell-type specific expression patterns of ZnT3

  • Identify co-expression networks associated with ZnT3 function

  • Compare expression profiles across brain regions and in disease states

• Cryo-electron microscopy:

  • Determine high-resolution structure of ZnT3 protein

  • Investigate conformational changes associated with zinc transport

  • Examine protein complexes involving ZnT3 at synaptic vesicles

How can researchers effectively study the regulation of SLC30A3 expression and function?

To investigate the regulation of SLC30A3 expression and function, implement these methodological approaches:

• Promoter analysis:

  • Identify regulatory elements in the SLC30A3 promoter region

  • Use reporter gene assays to assess promoter activity under various conditions

  • Examine effects of transcription factors on SLC30A3 expression

• Post-translational modification studies:

  • Investigate phosphorylation, ubiquitination, or other modifications

  • Use site-directed mutagenesis to identify key regulatory residues

  • Correlate modifications with transporter activity and localization

• Trafficking mechanisms:

  • Track movement from synthesis to synaptic vesicles

  • Identify proteins involved in proper localization

  • Examine effects of activity-dependent regulation on trafficking

• microRNA regulation:

  • Identify microRNAs that target SLC30A3 mRNA

  • Validate interactions using reporter assays

  • Manipulate microRNA levels to assess effects on ZnT3 expression

• Activity-dependent regulation:

  • Examine changes in ZnT3 expression following neuronal activation

  • Investigate signaling pathways connecting synaptic activity to ZnT3 regulation

  • Correlate activity-dependent changes with functional outcomes in zinc homeostasis

What methodological approaches are recommended for studying SLC30A3 in human pathological samples?

When investigating SLC30A3 in human pathological specimens, consider these methodological guidelines:

• Post-mortem tissue handling:

  • Standardize post-mortem interval and fixation protocols

  • Document pH and other tissue quality parameters

  • Use appropriate preservation methods to maintain antigen integrity

• Antigen retrieval optimization:

  • Test multiple retrieval methods (heat-induced, enzymatic)

  • Optimize pH and buffer composition for maximum signal recovery

  • Balance retrieval strength with tissue preservation

• Signal amplification techniques:

  • Consider tyramide signal amplification for low-abundance detection

  • Use polymer-based detection systems for increased sensitivity

  • Optimize antibody concentration through careful titration experiments

• Quantification approaches:

  • Develop standardized image acquisition parameters

  • Use automated analysis algorithms to reduce subjective interpretation

  • Include internal standards for cross-sample normalization

• Comparative analysis strategies:

  • Match cases and controls for age, sex, and other relevant variables

  • Analyze multiple brain regions with varying pathological involvement

  • Correlate findings with clinical and neuropathological data

How can SLC30A3 antibodies be utilized in biomarker development research?

For investigating SLC30A3 as a potential biomarker, implement these research strategies:

• Tissue microarray analysis:

  • Screen large cohorts of pathological samples with standardized staining

  • Quantify ZnT3 expression changes across disease stages

  • Correlate findings with clinical parameters and outcomes

• Cerebrospinal fluid (CSF) detection methods:

  • Develop sensitive ELISA or other immunoassays for ZnT3 detection

  • Validate assay performance with appropriate controls

  • Compare levels between patient groups and control subjects

• Correlation with existing biomarkers:

  • Analyze relationships between ZnT3 and established disease markers

  • Assess whether ZnT3 provides complementary or independent information

  • Evaluate ZnT3 in multimarker panels for improved diagnostic accuracy

• Longitudinal studies:

  • Track ZnT3 changes over disease progression

  • Assess utility for monitoring therapeutic interventions

  • Determine prognostic value through long-term follow-up

• Cross-platform validation:

  • Confirm findings using multiple methodological approaches

  • Validate antibody-based findings with orthogonal techniques (e.g., mass spectrometry)

  • Establish reproducibility across different research centers